Picture Kentro Design Is Key to Your Success Berlin 650x100px
Document › Details

Domain Therapeutics S.A.. (4/17/24). "Press Release: Domain Therapeutics Appoints Sean A. MacDonald as Chief Executive Officer". Strasbourg, Motnreal, QC & Boston, MA.

Organisations Organisation Domain Therapeutics S.A.
  Group Domain Therapeutics (Group)
  Organisation 2 iOnctura S.A.
  Group iOnctura (Group)
Products Product biopharmaceutical
  Product 2 cancer immunotherapy (immuno-oncology, I-O)
Persons Person Loyer, Annie-Florence (NewCap 201504)
  Person 2 Rulleau, Laurence (CTI Life Sciences 202205 Managing Partner)

> Sean will drive the Company through its next phase of growth and bring its highly promising pipeline through clinical development

> He brings more than 20 years of senior executive experience in the life science industry across business development, operations, and strategy

Domain Therapeutics (“Domain” or “the Company”), a global clinical-stage biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the appointment of Sean A. MacDonald as its Chief Executive Officer (CEO).

Sean, formerly Executive Strategic Advisor and most recently Chief Business Officer of Domain Therapeutics, has played a pivotal role over the past year in defining, alongside Domain’s management team, both corporate and clinical strategy. His efforts have been instrumental in positioning the development stage assets of Domain’s proprietary portfolio of GPCR-targeting immunotherapies. Sean’s in-depth knowledge and experience within all aspects of Domain’s operations, will be invaluable in driving the Company’s next phase of growth, leading and executing the Series B fundraising. As he steps into his new role as CEO, he will continue to pave the way for Domain towards maturing into a global clinical company. His leadership will be crucial in advancing and expanding Domain’s innovative portfolio of pioneering anticancer candidates.

Sean has a proven international track record of success in strategy and business development in several executive positions in the pharmaceutical industry (iOnctura, Cosmo Pharmaceuticals, Corbin Therapeutics Inc, Pharmascience Inc.), leading and closing multiple deals, including mergers and acquisitions, critical investments, fundraising and licensing activities, whilst building successful biotech companies in North America and Europe. In addition, he currently serves as a Board Director at Edesa Biotech.

Laurence Rulleau, Chair of the Board of Directors of Domain Therapeutics, said: “Sean’s profound understanding of Domain and strategic and operational expertise, executing deals at the most senior levels of business development and planning, makes him ideal to be at the operative helm of the Company as CEO. The Board’s unanimous decision ensures Domain is in a solid position to maximise its strong growth prospects. I am confident that this new leadership will drive Domain’s evolution as a global cancer company and move the Company forward towards even greater success to the benefit of cancer patients and their families. Sean succeeds Anthony Johnson, who I’d like to thank for his support of the Company.

Sean A. MacDonald, Chief Executive Officer of Domain Therapeutics, commented: “2024 is set to be a pivotal year for the Company and I am honoured to have been given the opportunity to lead and support the tremendous talent at Domain. Over the past several months, I have witnessed first-hand the remarkable strength of our team and the exceptional science we are developing. I look forward to continuing to drive our programs forward through the clinic and bring better and more effective treatment options to cancer patients worldwide.”


For more information, please contact:

ICR Consilium
Amber Fennell, Namrata Taak, Andrew Stern
Tel: +44 (0)20 3709 5813

Yucatan (for French media)
Annie-Florence Loyer
Tel: +33 (0)

About Domain Therapeutics

Domain Therapeutics, a global clinical-stage biopharmaceutical company, is developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes but still underexploited in immuno-oncology, to unlock new possibilities in cancer. As the leading GPCRs immuno-oncology company, Domain aims to beat resistance to immune modulation within the tumor microenvironment by unveiling therapeutic potential of GPCRs to defeat cancer. Two decades of solid GPCR expertise, validated through multiple pharma partnerships across various therapeutic areas and associated to a world-class drug discovery platform, enable the Company to deepen the understanding of cancer biology and deliver the next generation of immunotherapies to patients.

Domain’s proprietary programs include DT-7012, a Treg-depleting CCR8 antibody, DT-9045, a first-in-class PAR2 negative allosteric modulator, and DT-9081, an EP4 receptor antagonist alongside the M1069, an A2aR/A2b receptor antagonist identified in partnership with Merck KGaA. The Company has also an optimized pipeline of best-in-class and first-in-class GPCR targets selected through Domain’s proprietary cross-validation drug discovery and development platform.

Since 2022, the Company raised €51m ($55m) in series A to progress preclinical and clinical development of its high-value drug candidates to address GPCR-mediated immunosuppression. Domain is supported by leading international venture capital firms from Europe (3B Future Health Fund, Seventure, Schroders, Omnes, Turenne, Theodorus), Asia (Panacea and Viva) and North America (CTI Life Science, adMare).

Record changed: 2024-05-08


Picture Berlin Partner BIO 2024 International Convention San Diego 650x200px

More documents for Domain Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner BIO 2024 International Convention San Diego 650x300px

» top